Director David Schaffer resigns from 4D Molecular Therapeutics board

4D Molecular Therapeutics, Inc.

David Schaffer resigned from the Board and its Nominating and Corporate Governance and Science & Technology Committees, effective February 17, 2022.
He also intends to terminate his consulting agreement with the Company.
Resignation is not due to any disagreement with the Company or Board regarding operations, policies, or practices.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Schaffer

Director

FDMT · 4D Molecular Therapeutics, Inc.

Effective: 2022-02-17
Filed: February 22, 2022, 6:59 PM ET

On February 17, 2022, David Schaffer, Ph.D. delivered notice of his resignation from the Board of Directors (the "Board") of 4D Molecular Therapeutics, Inc. (the "Company") including his roles on the Nominating and Corporate Governance Committee and Science & Technology Committee, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Schaffer resigned as Director at 4D Molecular Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 17, 2022, David Schaffer, Ph.D. delivered notice of his resignation from the Board of Directors (the "Board") of 4D Molecular Therapeutics, Inc. (the "Company") including his roles on the Nominating and Corporate Governance Committee and Science & Technology Committee, effective immediately.

View on SEC.gov

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-048643

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.